The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,118.00
Ask: 12,120.00
Change: -38.00 (-0.31%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,138.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-More sceptics on the EU recovery fund

Mon, 23rd Nov 2020 09:55

* European shares hit highest since end February

* AstraZeneca COVID-19 vaccine can be 90% effective

* Vaccine shots could reach Americans by mid-December
Welcome to the home for real-time coverage of markets brought to
you by Reuters reporters. You can share your thoughts with us at
markets.research@thomsonreuters.com

MORE SCEPTICS ON THE EU RECOVERY FUND (0939 GMT)

Though most investors seem pretty sure that at the end of
the day a deal on the EU recovery fund will be reached, some
analysts sound more cautious.

“The nice plan of a EUR 1 trillion budget and the EUR ¾
trillion recovery fund has been put on ice and is at risk,”
according to Commerzbank analysts.

Commerzbank points to “the lack of liberal views in Eastern
Europe.”

It is true that up to now it “did not really bother anyone
in a material manner,” but “Western European tax-payers do not
understand why they should finance Orban and Kaczynski with
their taxes,” it says in a research note.

Warsaw and Budapest have refused to back the EU financial
plan, even though they are beneficiaries, because the money is
conditional on respecting the rule of law.

Both countries are under EU investigation and with the
condition in place they risk losing access to tens of billions
of euros. The EU Parliament said it would not accept any
dilution of a rule-of-law condition.

The EU recovery fund supported the euro and made government
bond yield spreads tighten significantly as it has been seen as
a game changer towards a more cooperative Union.

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: STOXX BACK TO FEB HIGHS (0822 GMT)

It's risk on as Monday trading starts here in Europe with
upbeat vaccine news from AstraZeneca and M&A activity
fuelling gains in beaten-down sectors and helping lift the
broader STOXX 600 benchmark back to end-February highs.

Oil and bank stocks are leading sectoral gainers with a
surge of more than 1%, while defensive plays are slightly
underperforming with utilities and healthcare posting slight
losses.

Here's your opening snapshot:

(Danilo Masoni)

*****

BANK M&A, DEALMAKING, ASTRAZENECA ON OUR RADAR (0745 GMT)

The positive mood seen is Asia is set to spill over to
Europe at the open today with fresh dealmaking activity in banks
and other sectors, along with AstraZeneca's vaccine
update, looking set to give investors more reasons to cheer.

Credit Agricole launched a cash offer to buy small
Italian bank Credito Valtellinese, offering a premium
of about 20% to Friday's closing price.

In the same sector, Reuters reported that Italy's Treasury
picked advisers to secure a merger deal for bailed-out bank
Monte dei Paschi, while Bloomberg said talks with UniCredit on
MPS's takeover have intensified.

Meantime, private equity firm Elliott has made a non-binding
proposal to acquire Aryzta but the Swiss frozen baked
goods maker said it was looking at other options.

Still in M&A, UK roadside recovery group AA has
received a proposal regarding a 35 pence a share cash offer
, while reports said Private equity firm CVC has
joined the race for Bilfinger, sending its shares up
5.6%.

Hellofresh shares are down 5.3% after the company
said it bought Factor75, a U.S. provider of fully-prepared
meals, for up to $277 million in cash.

In COVID-19 treatment news, AstraZeneca said its
vaccine for the novel coronavirus, developed along with the
University of Oxford, could be around 90% effective under one
dosing regimen.

Elsewhere, French food group Danone has announced
new cost-savings targets and said it planned to become a more
"local-first" organization worldwide, as part of efforts to
adapt to a post COVID-19 market.

Prosus has reported core earnings for the six
months ended Sept. 30. grew by 29% to $2.2 billion, as proceeds
from its lucrative stake in Tencent offset losses at its other
online businesses.

(Danilo Masoni)

*****

VACCINE OPTIMISM SET TO LIFT EUROPEAN SHARES (0641 GMT)

European shares are set to rise at the open today after the
weekend brought fresh optimism over a rapid vaccine deployment
in the U.S., while flash PMIs for November this morning will be
eyed for a glimpse over the health of region's economy.

EuroSTOXX50 and FTSE futures are up 0.4%
and 0.3% respectively following gains overnight in Asia that
lifted MSCI's broadest index of Asia-Pacific shares outside
Japan to a new record high.

A top U.S. official said on Sunday that the first vaccines
could be given to U.S. healthcare workers and others recommended
by mid-December.

(Danilo Masoni)

*****

More News
Today 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
Today 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
Today 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.